IL33 and chronic asthma: In addition, blockade of IL-33 signaling has been shown to limit the development of ILC2-mediated chronic asthma (63), with the administration of IL-33 activating ILC2-dependent lung inflammatory responses and goblet cell hyperplasia (12).